News
Current report No. 7/2023 – Successful tender for the supply of Company’s products to the Persian Gulf countries
Date: April 26, 2023, time: 04:10 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. The Management Board of Celon Pharma S.A. (“Company”) hereby informs that on April 26, 2023, the Company was informed by Glenmark Pharmaceuticals Ltd. with its registered seat in India (“Glenmark”) about a positiveRead more »
Current report No. 6/2023 – Allocation of A-series subscription warrants to eligible persons under the Incentive Program for Members of the Management Board of the Company for 2022
Date prepared: April 25, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Allocation of A-series subscription warrants to eligible persons under the Incentive Program for Members of the Management Board of the Company for 2022 Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. The Management BoardRead more »
Current report No. 5/2023 – Change of the date of publication of the annual report for 2022
Date prepared: 17/04/2023 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Management Board of Celon Pharma S.A. (“Company”) regarding the change of the date of publication of the annual report for 2022. This report was published on April 26, 2023. In accordance with theRead more »
Current report No. 4/2023 – Cancellation of the managing person
Date: April 12, 2023 Legal basis: Article 17 of the Market Abuse Regulation (MAR) – inside information. Management Board of Celon Pharma S.A. (“Company”) informs that on April 12, 2023, the Supervisory Board of the Company adopted a resolution to dismiss, as of April 12, 2023, Mr. Jacek Glinka from the position of a memberRead more »
Current report No. 3/2023 – Information regarding the Company’s meeting with the Food and Drug Administration (FDA) under the End of Phase II (EOP2) meeting procedure for Celon’s esketamine DPI (Falkieri) project
Date: February 24, 2023, 10:44 AMLegal basis: Article 17 of the Market Abuse Regulation (MAR) – inside information. The Management Board of Celon Pharma S.A. (“Company”) hereby informs that on February 23, 2023, the so-called End of Phase II meeting took place. The participants included, among others, the Division of Psychiatry at the Food andRead more »
Current report No. 2/2023 – Receipt of a notification regarding a change in the total number of votes in the Company
Date prepared: 06/02/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Receipt of a notification regarding a change in the total number of votes in the Company Legal basis: Article 70 point 1 of the Act on Public Offering – acquisition or disposal of a significant block of shares Content of the report: TheRead more »
Current report No. 1/2023 – Dates for submitting periodic reports in 2023
Date prepared: 25/01/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Dates for submitting periodic reports in 2023 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: Acting pursuant to Article 80 subs. 1 of the Regulation of the MinisterRead more »
Current report No. 28/2022 – Signing of an agreement on implementing and co-funding Celon Pharma S.A.’s project on a new therapeutic target for the FGF1 protein analogue
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information, time: 06:37 PM Content of the report: The Management Board of Celon Pharma S.A. (“Company”, “Beneficiary”) hereby informs that on December 6, 2022, an agreement was signed between the Company and the Medical Research Agency (“Agency”) on implementing and co-fundingRead more »
Current report No. 27/2022 – Signing of an agreement on implementing and co-funding Celon Pharma S.A.’s project on improving drug safety by implementing innovative forms of orally administered medicinal products to Celon Pharma S.A.’s in-house production
Date prepared: December 1, 2022, 08:35 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Content of the report: The Management Board of Celon Pharma S.A. (“Company”, “Beneficiary”) hereby informs that on December 1, 2022 an agreement was signed between the Company and the Medical Research Agency (“Agency”)Read more »
Current report No. 26/2022 – Conclusion of the agreement on joint development and commercialization of an inhalation drug containing fluticasone and salmeterol in the US
Current report No. 26/2022 Date prepared: 29/11/2022 Abbreviated name of the issuer: CELON PHARMA S.A. Topic Conclusion of the agreement on joint development and commercialization of an inhalation drug containing fluticasone and salmeterol in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Content of the report:Read more »